Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT.
about
CMV in Hematopoietic Stem Cell TransplantationPreventing stem cell transplantation-associated viral infections using T-cell therapyTranslational challenges of human herpesvirus 6 chromosomal integrationDiagnosis of cytomegalovirus pneumonia by quantitative polymerase chain reaction using bronchial washing fluid from patients with hematologic malignanciesGraft-versus-host disease-associated angiomatosis: a clinicopathologically distinct entity.The European LeukemiaNet: achievements and perspectives.Prophylaxis and therapy of viral infections in pediatric patients treated for malignancy.Clinical significance of quantifying Pneumocystis jirovecii DNA by using real-time PCR in bronchoalveolar lavage fluid from immunocompromised patients.Simultaneous human herpesvirus 6-associated encephalitis and Guillain-Barré syndrome in a patient after matched unrelated donor haematopoietic stem cell transplantationHuman herpesvirus 6 infection after hematopoietic cell transplantation: is routine surveillance necessary?Cytomegalovirus reactivation after autologous stem cell transplantation in myeloma and lymphoma patients: A single-center studyInfectious complications in cord blood and T-cell depleted haploidentical stem cell transplantationCytomegalovirus Infection Management in Allogeneic Stem Cell Transplant Recipients: a National Survey in Spain.Clinical significance of low cytomegalovirus DNA levels in human plasma.Priorities for CMV vaccine developmentEfficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant RecipientsDiagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation.Co-infections with cytomegalovirus and human herpesvirus type 7 in adult Polish allogeneic haematopoietic stem cell transplant recipients.HHV-6 encephalitis in pediatric unrelated umbilical cord transplantation: a role for ganciclovir prophylaxis?Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein.HHV-8-related visceral Kaposi's sarcoma following allogeneic HSCT: report of a pediatric case and literature review.Viral pneumonias in immunocompromised adult hosts.Stem cell transplantation for lymphoma patients with HIV infection.Chromosomally integrated human herpesvirus 6: questions and answers.Molecular diagnosis and management of viral infections in hematopoietic stem cell transplant recipients.Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Quantification of cytomegalovirus viral load.Roseoloviruses in transplant recipients: clinical consequences and prospects for treatment and prevention trials.Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study.Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: what we do and do not know.Clinical characteristics and outcome of human herpesvirus-6 encephalitis after allogeneic hematopoietic stem cell transplantation.Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant.Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation.Comparison of automated nucleic acid extraction methods for the detection of cytomegalovirus DNA in fluids and tissues.Chronic and recurrent benign lymphadenopathy without constitutional symptoms associated with human herpesvirus-6B reactivation.Severe esophagitis associated with cytomegalovirus during concurrent chemoradiotherapy for esophageal cancer.Transmission of chromosomally integrated human herpesvirus 6 via cord blood transplantation.Gene Delivery Approaches for Mesenchymal Stem Cell Therapy: Strategies to Increase Efficiency and Specificity.Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.Cytomegalovirus Infection With Retinitis After Brentuximab Vedotin Treatment for CD30+ Lymphoma.
P2860
Q26740385-DD0F5E90-2D9A-41B4-BB0A-5337110A7FB7Q26801365-A76838E2-DBA9-4ACE-B78D-5C854A7DA61BQ28287943-913A5F89-F30A-4147-BE17-AB46830ECD55Q33889365-F3F5E640-0AD1-4EAD-AECF-8323604BF442Q34195672-3E1ABCD2-1B30-4B0D-BCBE-793DF561F0AEQ34451619-F8F5A5B0-4662-4DC8-8288-264E2C57B624Q35010358-5E000B85-A757-4265-A5D9-F52F80A6BBF1Q35689165-B93A20E4-5CA4-41B5-88B4-07320B0BC6FAQ35762061-204B67AC-7102-4E13-87BE-365EBC5716C6Q35774717-A08300F7-3ADF-47D4-A7C1-51E84A104DE3Q35793055-FA8195A2-CC32-49F4-BD2C-1CD0DA7D9D20Q35824950-7766E391-AA12-4232-A546-D40897DD66CDQ35868731-A1CB69C6-32B0-4CEE-A4C4-493277279B56Q36118750-961875BC-EAC7-44E3-82B9-A3938842754CQ36216553-FD259D22-39C5-4C86-BBF7-0C894DCF4D67Q37091612-7C21458D-6488-466C-A95F-EC1526C3AD68Q37426542-676F51AD-9745-4179-B4A6-C6F8722BD43DQ37501878-322F4A15-2D76-4748-8BC2-D4B9E060F1B2Q37618303-8AA424C6-3C09-4F85-B794-789D7F63D63BQ37630372-5B0AE7D0-3758-48E9-B651-50C3F7BBBA06Q37719674-2094204D-6D8A-481F-9638-ACC284ACA2EEQ37788451-E2EE5594-170C-4FB3-8A7C-FF9BA7EBD945Q37793405-94D91177-2805-4CD9-84FA-1547A6683F29Q37952634-59B7D171-9649-4BD7-9769-C48B7638D8A5Q38002109-C7E7D103-E22C-442C-90A7-5E8F626E2707Q38080794-3BEEA551-0B73-4C70-A105-86F2E5D24B73Q38171537-4FD489C5-A322-4678-8C60-002CA443CBA3Q38256992-3B4A348C-E4F5-417A-AED9-4B17C5B23127Q38264990-8F427C27-BFA9-47B1-A0C5-43B7F0C3647CQ38444117-C7D51D33-BFE1-4213-9940-5BAB467108C6Q38637173-4FD9A6A2-C519-45E8-B09A-779D1C1861ACQ38703120-2D80FA53-7BEF-4648-A0C7-9BEAC93C960BQ38797660-EE40FA41-BF6C-4971-B2F3-B92B40940684Q38875533-46C276DB-D886-4CEB-8EE9-5DAF516DEB5BQ38930292-276A2869-08C0-4EA2-899F-A7AE75247E7CQ39154605-21C229B6-5CB6-4561-A49A-FFB6CFBDD5D5Q40079621-9E7EE42B-3B2B-42CE-8FCC-6B012362C5CFQ40080450-F3B282FF-6EEB-4130-B522-82862EF9B362Q40092234-C471978E-A594-4C35-805E-C1DEDA591511Q40162651-3A947686-D46F-4094-8B7C-4EC647AC0E79
P2860
Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Management of CMV, HHV-6, HHV- ...... al malignancies and after SCT.
@en
Management of CMV, HHV-6, HHV- ...... al malignancies and after SCT.
@nl
type
label
Management of CMV, HHV-6, HHV- ...... al malignancies and after SCT.
@en
Management of CMV, HHV-6, HHV- ...... al malignancies and after SCT.
@nl
prefLabel
Management of CMV, HHV-6, HHV- ...... al malignancies and after SCT.
@en
Management of CMV, HHV-6, HHV- ...... al malignancies and after SCT.
@nl
P2093
P2860
P356
P1476
Management of CMV, HHV-6, HHV- ...... al malignancies and after SCT.
@en
P2093
C Cordonnier
D Engelhard
European Conference on Infections in Leukemia
J Styczynski
R de la Camara
P2860
P2888
P304
P356
10.1038/BMT.2008.162
P407
P50
P577
2008-06-30T00:00:00Z